Prostate cancer: 2-year ADT improves survival in patients receiving high-dose radiotherapy.
Clemens
C
Thoma
D000230:Adenocarcinoma / Q000628:therapy*; D000726:Androgen Antagonists / Q000008:administration & dosage*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D059248:Chemoradiotherapy / Q000379:methods*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy*; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal